Page 66 - Read Online

Wu et al. Hepatoma Res 2023;9:6 https://dx.doi.org/10.20517/2394-5079.2022.37 Page 13 of 15

22. Li S, Lyu N, Han X, et al. Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial
chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis. J Vasc
Interv Radiol 2021;32:1267-1276.e1. DOI PubMed
23. Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular
carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol 2022;40:468-80. DOI PubMed
24. Bteich F, Di Bisceglie AM. Current and future systemic therapies for hepatocellular carcinoma. Gastroenterol Hepatol (NY)
2019;15:266-72. PubMed PMC
25. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. DOI PubMed
26. Bruix J, Qin S, Merle P, et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. DOI
PubMed
27. Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose
regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol
2020;12:1758835920936932. DOI PubMed PMC
28. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J
Med 2018;379:54-63. DOI PubMed PMC
29. Zhu AX, Kang YK, Yen CJ, et al; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced
hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled,
phase 3 trial. Lancet Oncol 2019;20:282-96. DOI PubMed
30. Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin
Oncol 2020;38:4317-45. DOI PubMed
31. Gao X, Huang H, Wang Y, et al. Tumor immune microenvironment characterization in hepatocellular carcinoma identifies four
prognostic and immunotherapeutically relevant subclasses. Front Oncol 2020;10:610513. DOI PubMed PMC
32. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised,
multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23:77-90. DOI PubMed
33. Rizzo A, Ricci AD, Di Federico A, et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular
carcinoma: Where do we stand? Front Oncol 2021;11:803133. DOI PubMed PMC
34. Fukuda H, Numata K, Moriya S, et al. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency
ablation-propensity score matching analysis. Radiology 2014;272:598-604. DOI PubMed
35. Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular
carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol 2014;109:1891-9. DOI PubMed
36. Kan X, Jing Y, Wan QY, Pan JC, Han M, Yang Y, Zhu M, Wang Q, Liu KH. Sorafenib combined with percutaneous radiofrequency
ablation for the treatment of medium-sized hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2015;19:247-55. PubMed
37. Bruix J, Takayama T, Mazzaferro V, et al; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or
ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-54. DOI PubMed
PMC
38. Jin M, Yu Q, Liu Y, Xu W, Fu X, Ji B. Safety and efficacy of physical thermal ablation combined sorafenib for hepatocellular
carcinoma: a meta-analysis. J Clin Transl Hepatol 2021;9:149-159. DOI PubMed PMC
39. Wang F, Numata K, Komiyama S, et al. Combination therapy with lenvatinib and radiofrequency ablation for patients with
intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh class a liver function: a pilot study. Front
Oncol 2022;12:843680. DOI PubMed PMC
40. Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-
free survival for patients with hepatocellular carcinoma. Int J Cancer 2014;134:342-51. DOI PubMed
41. Bian H, Zheng JS, Nan G, et al. Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous
radiofrequency ablation. J Natl Cancer Inst 2014;106:dju239. DOI PubMed
42. Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Gastroenterology 2015;148:1383-91.e6. DOI PubMed
43. Lee JH, Lee JH, Lim YS, et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular
carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother 2019;68:23-32. DOI PubMed PMC
44. Wang X, Liu G, Chen S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular
carcinoma: a propensity score matching analysis. Int J Hyperthermia 2021;38:1519-28. DOI PubMed
45. Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in
advanced hepatocellular carcinoma. J Hepatol 2019;71:1164-74. DOI PubMed
90
46. Kaseb AO, Kappadath SC, Lee SS, et al. A Prospective phase II study of safety and efficacy of sorafenib followed by Y glass
microspheres for patients with advanced or metastatic hepatocellular carcinoma. J Hepatocell Carcinoma 2021;8:1129-45. DOI
PubMed PMC
47. Zhan C, Ruohoniemi D, Shanbhogue KP, et al. Safety of combined Yttrium-90 radioembolization and immune checkpoint inhibitor
immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol 2020;31:25-34. DOI PubMed